Nautilus Biotechnology remains a high-risk, pre-commercial entity with no revenue generation over the last ten quarters, necessitating a critical evaluation of its ability to reach market viability. The company's heavy reliance on R&D, which averaged $10.8 mil...
Price trend, volume and key moving averages
Trailing total returns as of 10/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 28, 2026 | -$0.11+18.5% vs -$0.14 | $190,000+90.0% vs $100,000 |
Q2 2026 Apr 28, 2026 | -$0.12+17.2% vs -$0.14 | — vs $250,000 |
Q1 2026 Feb 26, 2026 | -$0.11+21.4% vs -$0.14 | — vs $1M |
Q4 2025 Oct 27, 2025 | -$0.11+26.7% vs -$0.15 | — vs — |
SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2026 before market open on Tuesday, October 27, 2026.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT - Get Free Report) was the target of unusually large options trading on Monday. Stock traders bought 3,253 call options on the stock. This represents an increase of 1,427% compared to the average daily volume of 213 call options. Nautilus Biotechnology Stock Performance NAUT stock traded up $0.34 during midday trading
You can't buy Neuralink stock yet, but its supply chain is already public. Here are the brain-computer interface stocks to watch before the Neuralink IPO.
First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending across disease areas First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending across disease areas
Benchmark NAUT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Nautilus Biotechnolgy, Inc. (NAUT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.24 | $412.31M | -6.89 | — | — | -32.27% | — | |
| $69.21 | $3.58B | -173.03 | 13.79% | 24.23% | 32.81% | — | |
| $1.97 | $108.31M | -1.54 | 15.57% | -490.71% | -27.23% | — | |
| $11.66 | $4.28B | -10.50 | 178.54% | -2001.59% | -26.67% | — | |
| $269.42 | $40.76B | 49.43 | -0.78% | 18.36% | 31.08% | — | |
| $2.11 | $655.37M | -1.16 | 3.89% | -82.49% | -4961.74% | — |
Nautilus Biotechnolgy, Inc. (NAUT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Nautilus Biotechnolgy, Inc. (NAUT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 28, 2026·SEC
Jun 18, 2026·SEC
Apr 28, 2026·SEC
Get notified when NAUT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Nautilus Biotechnolgy, Inc. (NAUT) stock FAQ — growth, dividends, profitability & financials explained
Nautilus Biotechnolgy, Inc. (NAUT) reported $0.2M in revenue for fiscal year 2025.
Nautilus Biotechnolgy, Inc. (NAUT) reported a net loss of $56.5M for fiscal year 2025.
Nautilus Biotechnolgy, Inc. (NAUT) has a return on equity (ROE) of -32.3%. Negative ROE indicates the company is unprofitable.
Nautilus Biotechnolgy, Inc. (NAUT) had negative free cash flow of $51.9M in fiscal year 2025, likely due to heavy capital investments.
